RU2752620C2 - Модифицированные углеводами частицы и порошкообразные композиции для модуляции иммунного ответа - Google Patents

Модифицированные углеводами частицы и порошкообразные композиции для модуляции иммунного ответа Download PDF

Info

Publication number
RU2752620C2
RU2752620C2 RU2017145397A RU2017145397A RU2752620C2 RU 2752620 C2 RU2752620 C2 RU 2752620C2 RU 2017145397 A RU2017145397 A RU 2017145397A RU 2017145397 A RU2017145397 A RU 2017145397A RU 2752620 C2 RU2752620 C2 RU 2752620C2
Authority
RU
Russia
Prior art keywords
particles
antigen
carbohydrate
tolerance
cells
Prior art date
Application number
RU2017145397A
Other languages
English (en)
Russian (ru)
Other versions
RU2017145397A3 (enExample
RU2017145397A (ru
Inventor
Пол Дж. БРАЙС
Карен Б. ЧИЭНЬ
Original Assignee
Нортвестерн Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нортвестерн Юниверсити filed Critical Нортвестерн Юниверсити
Publication of RU2017145397A publication Critical patent/RU2017145397A/ru
Publication of RU2017145397A3 publication Critical patent/RU2017145397A3/ru
Application granted granted Critical
Publication of RU2752620C2 publication Critical patent/RU2752620C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Biomedical Technology (AREA)
RU2017145397A 2015-05-27 2016-05-27 Модифицированные углеводами частицы и порошкообразные композиции для модуляции иммунного ответа RU2752620C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562167054P 2015-05-27 2015-05-27
US62/167,054 2015-05-27
PCT/US2016/034765 WO2016191723A1 (en) 2015-05-27 2016-05-27 Carbohydrate-modified particles and particulate formulations for modulating an immune response

Publications (3)

Publication Number Publication Date
RU2017145397A RU2017145397A (ru) 2019-06-28
RU2017145397A3 RU2017145397A3 (enExample) 2019-12-02
RU2752620C2 true RU2752620C2 (ru) 2021-07-29

Family

ID=57393770

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017145397A RU2752620C2 (ru) 2015-05-27 2016-05-27 Модифицированные углеводами частицы и порошкообразные композиции для модуляции иммунного ответа

Country Status (12)

Country Link
US (3) US20160346382A1 (enExample)
EP (1) EP3302446A4 (enExample)
JP (3) JP6882269B2 (enExample)
KR (1) KR102808155B1 (enExample)
CN (2) CN108024969A (enExample)
AU (1) AU2016267671B2 (enExample)
BR (1) BR112017025422A2 (enExample)
IL (2) IL293655B2 (enExample)
MX (1) MX2017015127A (enExample)
RU (1) RU2752620C2 (enExample)
WO (1) WO2016191723A1 (enExample)
ZA (1) ZA201708600B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114042441A (zh) * 2021-12-09 2022-02-15 云南师范大学 在血液灌流树脂微球表面修饰并固载肝素的方法及其制备的吸附剂
US12194435B2 (en) 2017-07-28 2025-01-14 Kimberly-Clark Worldwide, Inc. Nanoporous superabsorbent particles

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
JP7653696B2 (ja) 2016-12-09 2025-03-31 ノースウエスタン ユニバーシティ 骨形成促進温度応答性巨大分子
WO2018209259A1 (en) * 2017-05-11 2018-11-15 Northwestern University Intravascular retrievable cell delivery system
BR112021004081A2 (pt) * 2018-09-04 2021-05-25 Ecole Polytechnique Federale De Lausanne (Epfl) nanopartículas virucidas, composição farmacêutica, composição virucida, método de desinfecção e/ou esterilização, dispositivo e uso das nanopartículas virucidas
GB201819759D0 (en) * 2018-12-04 2019-01-23 Phytoquest Ltd Bioactive phytochemicals in zizphus and guarana
CN115212198A (zh) * 2021-04-15 2022-10-21 北京大学第三医院（北京大学第三临床医学院） 一种组合物在制备预防、缓解、治疗泪腺功能低下的药物方面的应用
CN113143939A (zh) * 2021-06-07 2021-07-23 长春中医药大学 贝母素甲在制备预防和/或治疗溃疡性结肠炎药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036001A2 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd Interferon gamma conjugates
RU2268749C2 (ru) * 1999-11-12 2006-01-27 Максиджен Холдингз Лтд КОНЪЮГАТЫ γ-ИНТЕРФЕРОНА
RU2011125366A (ru) * 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
WO2013144811A2 (en) * 2012-03-26 2013-10-03 Uti Limited Partnership Methods and compositions for treating inflammation
RU2497542C2 (ru) * 2008-10-12 2013-11-10 Массачусетс Инститьют Оф Текнолоджи Нацеливание на антигенпрезентирующие клетки иммунонанотерапевтических средств
WO2015066535A1 (en) * 2013-11-01 2015-05-07 Yale University Modular particles for immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040047866A1 (en) * 2002-09-09 2004-03-11 President And Fellows Of Harvard College Immunomodulatory methods using carbohydrate antigens
US9267937B2 (en) * 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
EP3939572B1 (en) * 2012-04-12 2024-03-27 Yale University Vehicles for controlled delivery of different pharmaceutical agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036001A2 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd Interferon gamma conjugates
RU2268749C2 (ru) * 1999-11-12 2006-01-27 Максиджен Холдингз Лтд КОНЪЮГАТЫ γ-ИНТЕРФЕРОНА
RU2497542C2 (ru) * 2008-10-12 2013-11-10 Массачусетс Инститьют Оф Текнолоджи Нацеливание на антигенпрезентирующие клетки иммунонанотерапевтических средств
RU2011125366A (ru) * 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
WO2013144811A2 (en) * 2012-03-26 2013-10-03 Uti Limited Partnership Methods and compositions for treating inflammation
WO2015066535A1 (en) * 2013-11-01 2015-05-07 Yale University Modular particles for immunotherapy

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194435B2 (en) 2017-07-28 2025-01-14 Kimberly-Clark Worldwide, Inc. Nanoporous superabsorbent particles
CN114042441A (zh) * 2021-12-09 2022-02-15 云南师范大学 在血液灌流树脂微球表面修饰并固载肝素的方法及其制备的吸附剂
CN114042441B (zh) * 2021-12-09 2024-05-03 云南师范大学 在血液灌流树脂微球表面修饰并固载肝素的方法及其制备的吸附剂

Also Published As

Publication number Publication date
RU2017145397A3 (enExample) 2019-12-02
KR102808155B1 (ko) 2025-05-16
IL293655B1 (en) 2024-12-01
JP6882269B2 (ja) 2021-06-02
KR20180012796A (ko) 2018-02-06
AU2016267671A1 (en) 2018-01-18
CN108024969A (zh) 2018-05-11
BR112017025422A2 (pt) 2018-08-07
IL255944A (en) 2018-01-31
JP7369734B2 (ja) 2023-10-26
MX2017015127A (es) 2018-06-22
JP2018515627A (ja) 2018-06-14
IL255944B (en) 2022-07-01
US20210205443A1 (en) 2021-07-08
IL293655B2 (en) 2025-04-01
JP2021130665A (ja) 2021-09-09
US20160346382A1 (en) 2016-12-01
JP2023130428A (ja) 2023-09-20
CN117815381A (zh) 2024-04-05
IL293655A (en) 2022-08-01
WO2016191723A1 (en) 2016-12-01
EP3302446A1 (en) 2018-04-11
ZA201708600B (en) 2022-05-25
EP3302446A4 (en) 2019-01-09
RU2017145397A (ru) 2019-06-28
AU2016267671B2 (en) 2021-09-23
US20230058412A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
RU2752620C2 (ru) Модифицированные углеводами частицы и порошкообразные композиции для модуляции иммунного ответа
Stabler et al. Engineering immunomodulatory biomaterials for type 1 diabetes
JP2019147799A (ja) 持続的免疫療法のための方法および組成物
Su et al. New opportunities for immunomodulation of the tumour microenvironment using chemical tools
US20120321665A1 (en) Compositions and methods for treating airway inflammatory diseases
Maulloo et al. Lymph node-targeted synthetically glycosylated antigen leads to antigen-specific immunological tolerance
Zhao et al. Transdermal microneedles alleviated rheumatoid arthritis by inducing immune tolerance via skin‐resident antigen presenting cells
Liu et al. Hyaluronidase-functionalized silica nanocarrier for enhanced chemo-immunotherapy through inducing immunogenic cell death
Gong et al. Tumor Microenvironment‐Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade‐Amplified Immune Response against Tumor Growth, Metastasis and Recurrence
KR20150028225A (ko) 항원-특이적 조절 ｔ 세포의 유도 방법
Huang et al. Advanced delivery strategies for immunotherapy in type I diabetes mellitus
Du et al. Diphtheria toxoid-derived T-helper epitope and α-galactosylceramide synergistically enhance the immunogenicity of glycopeptide antigen
Medina Biomaterial-mediated approaches for persistent, localized, and targeted delivery of immunomodulatory proteins
US20250186580A1 (en) A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
JP7629401B2 (ja) がんの治療又は予防に使用するための貪食可能な粒子
KR20240153600A (ko) 적어도 β-글루칸 또는 만난으로 구성되거나 또는 이를 포함하는 접합체
WO2019246408A2 (en) Antibody linked peptide based immunotherapy for type 1 diabetes
Verbeke Antigen-specific immune modulation using an injectable biomaterial
Saitoº et al. kk Results: The vaccine was well tolerated, Fifteen of 20 patients completed one cycle of vaccination and two